AbbVie, Galapagos aim to beat Vertex in CF
This article was originally published in Scrip
AbbVie has signed a $405m deal with Galapagos of Belgium which will see the two companies pool resources with the aim of developing a superior treatment for cystic fibrosis to Vertex Pharmaceuticals' Kalydeco (ivacaftor). More than a hundred staff from the two partners will work together to advance Galapagos's early-stage in-house research and develop CF transmembrane conductance regulator (CFTR) therapies.
You may also be interested in...
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.